"
Uiuce bus model
From 2013.igem.org
(Difference between revisions)
Ashleysmoy (Talk | contribs) |
Ashleysmoy (Talk | contribs) |
||
| (87 intermediate revisions not shown) | |||
| Line 9: | Line 9: | ||
/*the igem Global setting*/ | /*the igem Global setting*/ | ||
* { | * { | ||
| - | margin: | + | margin: 5; |
padding: 0; | padding: 0; | ||
-webkit-font-smoothing: antialiased; | -webkit-font-smoothing: antialiased; | ||
| Line 18: | Line 18: | ||
body{ | body{ | ||
color: #34495e; | color: #34495e; | ||
| + | width: 1000px; | ||
| + | margin: 0 auto; | ||
} | } | ||
#bodyContent h1, #bodyContent h2{ | #bodyContent h1, #bodyContent h2{ | ||
| Line 23: | Line 25: | ||
} | } | ||
h1, h2, h3, h4, h5, h6{ | h1, h2, h3, h4, h5, h6{ | ||
| - | padding-top: | + | padding-top: 100; |
| - | padding-bottom: | + | padding-bottom: 100; |
color: #34495e; | color: #34495e; | ||
} | } | ||
| Line 31: | Line 33: | ||
} | } | ||
#top-section{ | #top-section{ | ||
| - | height: | + | height:50px; |
border:none; | border:none; | ||
width:980px; | width:980px; | ||
| Line 55: | Line 57: | ||
height: 100%; | height: 100%; | ||
margin:0; | margin:0; | ||
| - | padding: | + | padding:50; |
| - | width:100%; | + | width: 100%; |
position: absolute; | position: absolute; | ||
background-color: #FFFFFF; | background-color: #FFFFFF; | ||
| Line 62: | Line 64: | ||
} | } | ||
a:visited{ | a:visited{ | ||
| - | color: # | + | color: #34495e; |
} | } | ||
/*the nav settings | /*the nav settings | ||
----------------------------------------------- */ | ----------------------------------------------- */ | ||
| + | ul.navbar-nav{margin: 0 -35px 25px 0;float: right;} | ||
.navbar-inverse .navbar-nav>.open>a, .navbar-inverse .navbar-nav>.open>a:hover, .navbar-inverse .navbar-nav>.open>a:focus{ | .navbar-inverse .navbar-nav>.open>a, .navbar-inverse .navbar-nav>.open>a:hover, .navbar-inverse .navbar-nav>.open>a:focus{ | ||
color: #1abc9c; | color: #1abc9c; | ||
| Line 71: | Line 74: | ||
} | } | ||
.navbar-inverse .navbar-nav>li>a{ | .navbar-inverse .navbar-nav>li>a{ | ||
| - | color: # | + | color: #1abc9c; |
} | } | ||
.navbar-inverse .navbar-nav>li>a:hover{ | .navbar-inverse .navbar-nav>li>a:hover{ | ||
| Line 78: | Line 81: | ||
} | } | ||
.navbar-inverse .navbar-brand{ | .navbar-inverse .navbar-brand{ | ||
| - | color: # | + | color: #1abc9c; |
padding: 0; | padding: 0; | ||
} | } | ||
.navbar-inverse .navbar-brand img{ | .navbar-inverse .navbar-brand img{ | ||
| - | + | height: 0px; | |
| - | + | ||
} | } | ||
.navbar-inverse .navbar-brand p{ | .navbar-inverse .navbar-brand p{ | ||
padding:12px 30px; | padding:12px 30px; | ||
| - | margin: | + | margin:10; |
} | } | ||
.navbar-inverse .navbar-brand:hover{ | .navbar-inverse .navbar-brand:hover{ | ||
| Line 118: | Line 120: | ||
.dropdown-submenu:hover>.dropdown-menu{display:block;} | .dropdown-submenu:hover>.dropdown-menu{display:block;} | ||
.dropdown-submenu>a:after{display:block;content:" ";float:right;width:0;height:0;border-color:transparent;border-style:solid;border-width:5px 0 5px 5px;border-left-color:#cccccc;margin-top:5px;margin-right:-10px;} | .dropdown-submenu>a:after{display:block;content:" ";float:right;width:0;height:0;border-color:transparent;border-style:solid;border-width:5px 0 5px 5px;border-left-color:#cccccc;margin-top:5px;margin-right:-10px;} | ||
| - | .dropdown-submenu:hover>a:after{border-left-color:# | + | .dropdown-submenu:hover>a:after{border-left-color:#cccccc} |
.dropdown-submenu.pull-left{float:none;}.dropdown-submenu.pull-left>.dropdown-menu{left:-100%;margin-left:10px;-webkit-border-radius:6px 0 6px 6px;-moz-border-radius:6px 0 6px 6px;border-radius:6px 0 6px 6px;} | .dropdown-submenu.pull-left{float:none;}.dropdown-submenu.pull-left>.dropdown-menu{left:-100%;margin-left:10px;-webkit-border-radius:6px 0 6px 6px;-moz-border-radius:6px 0 6px 6px;border-radius:6px 0 6px 6px;} | ||
| Line 125: | Line 127: | ||
position: relative; | position: relative; | ||
width: 100%; | width: 100%; | ||
| + | height: 50%; | ||
overflow: auto; | overflow: auto; | ||
font-size: 18px; | font-size: 18px; | ||
line-height: 24px; | line-height: 24px; | ||
text-align: center; | text-align: center; | ||
| - | color: # | + | color: #00a5ff; |
background: ; | background: ; | ||
box-shadow: 0 1px 2px rgba(0,0,0,.25); | box-shadow: 0 1px 2px rgba(0,0,0,.25); | ||
| Line 135: | Line 138: | ||
.banner ul { | .banner ul { | ||
list-style: none; | list-style: none; | ||
| - | width: | + | width: 100%; |
margin: 0; | margin: 0; | ||
} | } | ||
| Line 141: | Line 144: | ||
display: block; | display: block; | ||
float: left; | float: left; | ||
| - | width: | + | width: 100%; |
| - | min-height: | + | min-height: 500px; |
-o-background-size: 100% 100%; | -o-background-size: 100% 100%; | ||
| Line 161: | Line 164: | ||
.banner h1, .banner h2 { | .banner h1, .banner h2 { | ||
font-size: 40px; | font-size: 40px; | ||
| - | line-height: 52px; | + | line-height: 52px; |
border-bottom:#fff; | border-bottom:#fff; | ||
color: #fff; | color: #fff; | ||
| Line 322: | Line 325: | ||
</head> | </head> | ||
<body> | <body> | ||
| + | <div> | ||
| + | <div class="container"> | ||
<div class="navbar navbar-inverse navbar-fixed-top" role="navigation"> | <div class="navbar navbar-inverse navbar-fixed-top" role="navigation"> | ||
<div class="navbar-header"> | <div class="navbar-header"> | ||
| Line 331: | Line 336: | ||
</button> | </button> | ||
<a class="navbar-brand" href="https://igem.org/Team_Wikis?year=2013"> | <a class="navbar-brand" href="https://igem.org/Team_Wikis?year=2013"> | ||
| - | <img src="https://static.igem.org/mediawiki/2013/7/7d/Ouc-igem1.png"> | + | <img border="0" src="https://static.igem.org/mediawiki/2013/7/7d/Ouc-igem1.png"> |
</a> | </a> | ||
| + | |||
| + | </button> | ||
| + | |||
<a class="navbar-brand" href="https://2013.igem.org/Team:UIUC_Entrepreneurs"> | <a class="navbar-brand" href="https://2013.igem.org/Team:UIUC_Entrepreneurs"> | ||
| - | < | + | <img align="middle" border="0" src="https://static.igem.org/mediawiki/2013/4/47/Uiuce_VivoSynth_LogoV2.PNG"> |
</a> | </a> | ||
| + | |||
| + | |||
</div> | </div> | ||
| + | </div> | ||
| + | |||
<div class="collapse navbar-collapse navbar-ex1-collapse"> | <div class="collapse navbar-collapse navbar-ex1-collapse"> | ||
<ul class="nav navbar-nav pull-right"> | <ul class="nav navbar-nav pull-right"> | ||
| - | <li><a href="https://2013.igem.org/Team:UIUC_Entrepreneurs"> | + | <li><a href="https://2013.igem.org/Team:UIUC_Entrepreneurs"><font size="5"><b>Home</b></font></a></li> |
| - | + | <li><a href="https://2013.igem.org/Uiuce_bus_model"><font size="5"><b>Business Model</b></font></a></li> | |
| - | + | <li><a href="https://2013.igem.org/Uiuce_modulab"><font size="5"><b>ModuLab</b></font></a></li> | |
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
<li class="dropdown"> | <li class="dropdown"> | ||
| - | <a class="dropdown-toggle" data-toggle="dropdown" href="#">About Us<b class="caret"></b></a> | + | <a class="dropdown-toggle" data-toggle="dropdown" href="#"><font size="5"><b>About Us</b></font><b class="caret"></b></a> |
| - | <ul id="menu2" class="dropdown-menu" role="menu" aria-labelledby="dropdownMenu"> | + | <ul id="menu2" class="dropdown-menu" role="menu" aria-labelledby="dropdownMenu"> |
| - | + | <li role="presentation"><a role="menuitem" tabindex="-1" href="https://2013.igem.org/Igeme_team">Our Team</a></li> | |
| - | <li role="presentation"><a role="menuitem" tabindex="-1" href="https://2013.igem.org/ | + | <li role="presentation"><a role="menuitem" tabindex="-1" href="https://2013.igem.org/Uiuce_advisory_board">Advisory Board</a></li> |
| - | + | <li role="presentation"><a role="menuitem" tabindex="-1" href="https://igem.org/Main_Page">iGEM</a></li> | |
| + | |||
| + | _TOC_ | ||
</ul> | </ul> | ||
</li> | </li> | ||
</ul> | </ul> | ||
</div> | </div> | ||
| - | </div> | + | </div> |
| + | </div> | ||
<!--the slidershow begin--> | <!--the slidershow begin--> | ||
| - | + | ||
| + | |||
| + | |||
<!--the slidershow end--> | <!--the slidershow end--> | ||
| - | |||
| - | |||
| - | |||
| - | |||
| - | + | ||
| - | + | <left><h3><b>Business Model</b></h3><hr></left> | |
| + | |||
| + | |||
| + | |||
| + | |||
</div> | </div> | ||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| + | <center><font size="3"><b> Business Overview</b></font><br></center> | ||
| + | <p><b>Customer Problem</b></p><br> | ||
| + | <p>The cloning process consists of several individual steps, each with its own equipment and machinery. It is complex, yet still requires a remarkable amount of human intervention. This results in errors, inconsistencies, and an overall delay in meeting significant synthetic biology milestones. Our team seeks to minimize this “human intervention” element by designing, prototyping, and commercializing an automated cloning system.</p><br> | ||
| - | < | + | <center><img src="https://static.igem.org/mediawiki/2013/e/ec/Uiuce_Igeme_customer_prob.png" width="400" height="294" alt="Pills" /></center><br><br> |
| - | < | + | |
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | </ | + | |
| - | < | + | <p><b>Our Solution</b></p><br> |
| - | + | <p>Our flagship product, ModuLab, is an automated system designed to optimize cloning, the underlying process of synthetic biology. The ultimate goals of ModuLab are to minimize error, maximize efficiency and provide synthetic biologists with feedback on every stage of the cloning process.</p><br><br><br> | |
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | <center><font size="3"><b> Competitive Analysis</b></font><br></center> | |
| - | < | + | |
| - | < | + | |
| + | <p><b>Direct Competition</b></p><br> | ||
| + | <p>Because of the relative youth of synthetic biology, there are currently no products that are able to fully conduct the cloning protocol from start to finish without human intervention. We could, however, experience competition from device manufacturers that produce some of the individual components of our system. As per our own research, the closest product to ModuLab is the Freedom EVO® Expression Workstation produced by Tecan Group Ltd.</p> | ||
| + | <center><img src="https://static.igem.org/mediawiki/2013/8/82/Uiuce_direct_comp.png" width="720" height="294" alt="Pills" /><br><br></center> | ||
| + | <p><b>Indirect Competition</b></p> | ||
| + | <p>Indirect competition to the field of synthetic biology as a whole is high, given other technologies that have been around for decades. In the specific niche market within which Vivosynth is positioned, however, such competition is negligible, because of the relative nonexistence of methods to fully automate the cloning protocol.</p><br> | ||
| - | < | + | <p><b>Future Competition </b></p> |
| - | + | <p>Future competition will likely come in the form of new advances in robotics and automation that will further optimize cloning. Vivosynth is uniquely suited to adapting to these new advances because of our close ties to the University of Illinois and our ability to modify our product(s) as and when it needs </p><br> | |
| + | |||
| + | <p><b> Competitive Advantage</b></p><br> | ||
| + | <p>Our product, ModuLab, would be unique in its ability to conduct the entire cloning protocol from start to finish without human intervention. As far as we know, there are no products capable of doing this. We believe such a product would dramatically increase the rate at which synthetic biology research and manufacturing progresses over the next decade. The product is also unique because it will be able to adapt to automate any lab machinery.</p><br><br> | ||
| + | |||
| + | <center><font size="3"><b> Market Analysis</b></font><br></center> | ||
| + | <p><b>Industry Profile</b></p><br> | ||
| + | <p>The global synthetic biology market is estimated to grow to $4.5 billion over the next three years. This is due to major developments in biomedicine, pharmaceutical drug synthesis, energy and environmental research, biomaterials, nanotechnology, and biosecurity. There have been significant investments in the industry by companies such as Amyris Inc, GeneScript, Bayer, and Blue Heron Biotechnologies. Additionally, developments in DNA synthesis and sequencing technologies and bioinformatics have catalyzed the progress of synthetic biology ever since the creation of the first synthetic cell in 2010. Synthetic biology is being recognized around the world as an emerging technology that has the potential to provide solutions to energy and food shortage, pollution, infectious diseases, and even climate change. The following diagram depicts the distribution of the global synthetic biology market share, as of 2011:</p><br><br> | ||
| + | |||
| + | <center><img src="https://static.igem.org/mediawiki/2013/4/4c/Uiuce_industrial_prof.png" width="500" height="294" alt="Pills" /><br><br></center> | ||
| + | |||
| + | <p><b>Marketing Strategy</b></p> | ||
| + | <p>Vivosynth will adopt a two-step marketing plan for commercializing ModuLab. It involves the systematic dissemination of our technologies to academic and research institutions at highly discounted rates, followed by the targeted selection of pharmaceutical companies and chemical manufacturers with our final full-price system. Intellectual property protection for our design will be obtained prior to the execution of our sales strategy.<br><br> | ||
| + | |||
| + | Next, the company will look to enter into distribution agreements for the registration and sales of its products in the United States, and eventually foreign countries. These distribution agreements will take the form of contracts with existing manufacturers of biotechnology devices, in order to achieve economies of scale. <br><br> | ||
| + | |||
| + | Vivosynth will also actively pursue online advertising, advertise our products at biotechnology oriented trade shows, and release a monthly newsletter to keep potential and current customers updated about product developments.<br><br> | ||
| + | |||
| + | <center><img src="https://static.igem.org/mediawiki/2013/3/37/Uiuce_marketing.png" width="720" height="294" alt="Pills" /><br><br><br><br></center> | ||
| + | |||
| + | |||
| + | <center><font size="3"><b> Past and Projected Timeline</b></font><br></center> | ||
| + | <p>Our business model has currently been implemented through the model creation phase. Next steps include cultivating relationships and licensing our technology to existing biotechnology device manufacturers.</p> | ||
| + | |||
| + | <center><img src="https://static.igem.org/mediawiki/2013/5/5b/Uiuce_timeline.png" width="720" height="294" alt="Pills" /><br><br><br><br><br></center> | ||
| + | |||
| + | |||
| + | <center><font size="3"><b>Financial Plan</b></font><br></center><br><br> | ||
| + | |||
| + | <center><img style="-webkit-user-select: none" src="https://static.igem.org/mediawiki/2013/9/9f/Uiuce_table_edit.png"></center> | ||
| + | |||
| + | |||
| + | |||
| + | |||
| + | <center><font size="3"><b>Vivosynth Technologies: Value Proposition</b></font><br></center> | ||
| + | <br><br> | ||
| + | |||
| + | |||
| + | |||
| + | |||
| + | <center><img src="https://static.igem.org/mediawiki/2013/c/c2/Uiuce_Capture2.PNG" width="720" height="294" alt="Pills" /></center> | ||
| + | <!--footer--> | ||
| + | |||
| + | <script src="http://netdna.bootstrapcdn.com/bootstrap/3.0.0/js/bootstrap.min.js"></script> | ||
| + | <script src="http://unslider.com/unslider.min.js"></script> | ||
| + | <script> | ||
| + | $(function() { | ||
| + | $('.banner').unslider(); | ||
| + | }); | ||
</script> | </script> | ||
| + | </body> | ||
</html> | </html> | ||
Latest revision as of 03:53, 29 October 2013
Business Model
Customer Problem
The cloning process consists of several individual steps, each with its own equipment and machinery. It is complex, yet still requires a remarkable amount of human intervention. This results in errors, inconsistencies, and an overall delay in meeting significant synthetic biology milestones. Our team seeks to minimize this “human intervention” element by designing, prototyping, and commercializing an automated cloning system.
Our Solution
Our flagship product, ModuLab, is an automated system designed to optimize cloning, the underlying process of synthetic biology. The ultimate goals of ModuLab are to minimize error, maximize efficiency and provide synthetic biologists with feedback on every stage of the cloning process.
Direct Competition
Because of the relative youth of synthetic biology, there are currently no products that are able to fully conduct the cloning protocol from start to finish without human intervention. We could, however, experience competition from device manufacturers that produce some of the individual components of our system. As per our own research, the closest product to ModuLab is the Freedom EVO® Expression Workstation produced by Tecan Group Ltd.
Indirect Competition
Indirect competition to the field of synthetic biology as a whole is high, given other technologies that have been around for decades. In the specific niche market within which Vivosynth is positioned, however, such competition is negligible, because of the relative nonexistence of methods to fully automate the cloning protocol.
Future Competition
Future competition will likely come in the form of new advances in robotics and automation that will further optimize cloning. Vivosynth is uniquely suited to adapting to these new advances because of our close ties to the University of Illinois and our ability to modify our product(s) as and when it needs
Competitive Advantage
Our product, ModuLab, would be unique in its ability to conduct the entire cloning protocol from start to finish without human intervention. As far as we know, there are no products capable of doing this. We believe such a product would dramatically increase the rate at which synthetic biology research and manufacturing progresses over the next decade. The product is also unique because it will be able to adapt to automate any lab machinery.
Industry Profile
The global synthetic biology market is estimated to grow to $4.5 billion over the next three years. This is due to major developments in biomedicine, pharmaceutical drug synthesis, energy and environmental research, biomaterials, nanotechnology, and biosecurity. There have been significant investments in the industry by companies such as Amyris Inc, GeneScript, Bayer, and Blue Heron Biotechnologies. Additionally, developments in DNA synthesis and sequencing technologies and bioinformatics have catalyzed the progress of synthetic biology ever since the creation of the first synthetic cell in 2010. Synthetic biology is being recognized around the world as an emerging technology that has the potential to provide solutions to energy and food shortage, pollution, infectious diseases, and even climate change. The following diagram depicts the distribution of the global synthetic biology market share, as of 2011:
Marketing Strategy
Vivosynth will adopt a two-step marketing plan for commercializing ModuLab. It involves the systematic dissemination of our technologies to academic and research institutions at highly discounted rates, followed by the targeted selection of pharmaceutical companies and chemical manufacturers with our final full-price system. Intellectual property protection for our design will be obtained prior to the execution of our sales strategy.
Next, the company will look to enter into distribution agreements for the registration and sales of its products in the United States, and eventually foreign countries. These distribution agreements will take the form of contracts with existing manufacturers of biotechnology devices, in order to achieve economies of scale.
Vivosynth will also actively pursue online advertising, advertise our products at biotechnology oriented trade shows, and release a monthly newsletter to keep potential and current customers updated about product developments.
Our business model has currently been implemented through the model creation phase. Next steps include cultivating relationships and licensing our technology to existing biotechnology device manufacturers.
